Sparrow Pharmaceuticals is collaborating with the University of Oxford and the University of Sheffield on DC-MACS, an investigator led, Phase 2 clinical study in the United Kingdom of clofutriben (SPI-62) for the treatment of autonomous cortisol secretion (ACS).

Sparrow Pharmaceuticals will present interim data from the ongoing Phase 2 trial of lead agent clofutriben in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) at the American College of Rheumatology Convergence 2024 conference. Sparrow also announced that the trial has been expanded with a fifth cohort based on encouraging results from the first four cohorts.

Sparrow Pharmaceuticals announced that the Phase 2 RESCUE trial of clofutriben for the treatment of endogenous Cushing’s syndrome is complete. Clofutriben has also been granted Orphan Drug Designation by the FDA for the treatment of endogenous Cushing’s syndrome.

Sparrow Pharmaceuticals today announced that it presented new data of its HSD-1 inhibitor, clofutriben in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) at the German Congress of Rheumatology (DGRh Kongress 2024) in Dusseldorf, Germany.

Sparrow Pharmaceuticals today presented data from an ongoing Phase 2 clinical trial that suggest HSD-1 inhibition can allow for effective treatment with glucocorticoid medicines with fewer side effects.

Sparrow Pharmaceuticals announced today that, to date, the HSD-1 inhibitor clofutriben (SPI-62) has normalized urine free cortisol (UFC) in >60% of patients with endogenous Cushing’s syndrome (EnCS) without suppressing serum cortisol to levels considered to indicate risk for adrenal insufficiency (AI).

Sparrow Pharmaceuticals’ David Katz, PhD, to Receive Outstanding Innovation Award at the 2024 Annual Endocrine Society Conference

Sparrow Pharmaceuticals has continued to expand its PROST! Phase 2 clinical trial (NCT05436652) of SPI-62 in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) with a fourth cohort.

Sparrow Pharmaceuticals today announced that the first patient has been dosed in the Phase 2 ACSpire study of SPI-62, a potent and selective HSD-1 inhibitor, for the treatment of autonomous cortisol secretion (ACS).

Sparrow Pharmaceuticals today announced the expansion of its PROST! Phase 2 clinical trial of SPI-62 in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) to include a third cohort.

Sparrow Pharmaceuticals today announced the first patient has elected to enroll in the open-label extension (OLE) phase of the RESCUE trial, a phase 2 clinical trial of SPI-62 for the treatment of ACTH-dependent Cushing’s syndrome. The long-term OLE will be open to patients who complete the initial RESCUE cross-over treatment protocol and then elect to continue to participate in the research.

Sparrow Pharmaceuticals will present the rationale that its lead candidate and HSD-1 inhibitor, SPI-62, is predicted to be associated with limited adrenal insufficiency risk in Cushing’s syndrome during a poster session at the Endocrine Society (ENDO) 2023 Annual Conference.

Sparrow Pharmaceuticals presented an ePoster on SPI-62 during a session, titled “Controlling intracellular cortisol: Can HSD-1 inhibition reduce Cushing’s syndrome morbidity and minimize adrenal insufficiency risk?” at the 25th European Congress of Endocrinology (ECE 2023).

Sparrow Pharmaceuticals has expanded its Phase 2 clinical trial of prednisolone in combination with SPI-62 for the treatment of polymyalgia rheumatica (PMR) with the introduction of a second cohort to the study.